Your kidneys filter about 700 mg of uric acid daily, reabsorbing most of it back into the bloodstream. The SLC2A9 gene encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, also called GLUT9, a voltage-driven urate transporter expressed in the proximal tubule of the kidney that handles most renal urate reabsorption — the protein responsible for setting your urate "baseline." The rs6814664 C>T variant sits within an intron of SLC2A9 and does not change the protein itself, but tags a broader regulatory signal that modulates how much urate your kidneys return to the bloodstream.

This variant is part of a cluster of intronic SLC2A9 SNPs identified in genome-wide association studies as tagging the same biological signal: variation in GLUT9 transport efficiency. As a tag SNP, rs6814664 captures the urate association through linkage disequilibrium with functional variants elsewhere in the gene.

The Mechanism

SLC2A9 encodes two kidney isoforms — GLUT9a (long form) located on the basolateral membrane of proximal tubule cells, which returns reabsorbed urate to the blood, and GLUT9b (short form) on the apical membrane. Together they form a "urate-recapture" system: urate filtered from blood enters the tubular lumen, is reabsorbed by apical transporters including URAT1, and then re-enters the circulation via GLUT9a.

Intronic variants in SLC2A9 are thought to exert their effects through altered gene expression rather than protein structure changes. The SLC2A9 locus contains active enhancers in hepatic and erythroid cell types, and fine-mapping studies²² fine-mapping studies
Wei et al. Abundant local interactions in the 4p16.1 region. Hum Mol Genet, 2014 identify epistatic interactions between intronic and intergenic variants that together explain about 6% of serum urate variance. The rs6814664 C allele likely tags regulatory haplotypes that drive higher GLUT9 expression or greater transport efficiency, resulting in more urate being returned to the blood.

The Evidence

Sex-specific effects are the defining feature of SLC2A9 intronic variants. The landmark KORA genome-wide scan by Döring et al.³³ Döring et al.
Döring A et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008 (n = 1,644 primary cohort plus three replication samples) showed that intronic SLC2A9 variants in introns 4 and 6 explain approximately 1.2% of serum urate variance in men but a striking 6% in women. Effect sizes were −0.23 to −0.36 mg/dL per protective allele copy, with women showing up to twice the effect size of men in replication cohorts. Separately, SLC2A9 isoform 2 expression was significantly associated with serum urate, explaining 3.5% of variance in men and 15% in women. This sex divergence likely reflects estrogen-mediated regulation of GLUT9 expression and the lower baseline urate levels in women, where relative changes are more detectable.

The SLC2A9 locus overall was characterised by Vitart et al.⁴⁴ Vitart et al.
Vitart V et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 2008 as the single strongest genetic determinant of serum urate, with variants explaining 1.7–5.3% of urate variance across Croatian, UK, and German samples. Variants at this locus were also associated with reduced fractional excretion of uric acid (less urate in the urine), confirming that the mechanism is impaired renal excretion rather than overproduction.

BMI interaction: A study in the Bruneck and Utah cohorts⁵⁵ study in the Bruneck and Utah cohorts
Döring A et al. Sex-specific association of SLC2A9 variants with uric acid levels is modified by BMI. 2008 (n = 2,669) found that SLC2A9 intronic variant effects on serum urate are amplified in individuals with higher BMI, with significant interaction p-values of 0.023–0.035. This means that C-allele carriers who are also overweight or obese accumulate a greater urate burden than the genetic effect alone would predict.

Population variation: The C allele shows striking population stratification: ~90% in East Asians, ~57% in Europeans, ~32% in Africans. This gradient mirrors the known cross-ancestry differences in serum urate and gout prevalence — East Asian populations, who carry the highest C-allele burden at this locus, also have among the highest gout prevalence globally.

Practical Actions

Intronic SLC2A9 variants affect urate reabsorption efficiency. Dietary and metabolic levers that directly modulate the urate load reaching those transporters are the most tractable interventions.

The key dietary modulators of serum urate for C-allele carriers are: organ meats (liver, kidney, sweetbreads) and red meat, which supply large purine loads; alcohol — particularly beer and spirits, which elevate urate both through purine content and by competing with urate for renal excretion; and high-fructose beverages, since fructose catabolism generates inosine monophosphate (a direct urate precursor) and fructose itself competes with urate for tubular exchange via SLC2A9. Dairy and coffee are associated with modestly lower serum urate in epidemiological studies.

The crystalisation threshold for monosodium urate is 6.8 mg/dL at physiological temperature. Maintaining serum urate below 6.0 mg/dL is a widely used clinical target to prevent and dissolve crystals and suppress gout flares.

Interactions

With rs3733591 (SLC2A9 Arg265His): rs3733591 is the larger-effect coding variant at SLC2A9, with the C allele adding ~0.65 mg/dL per copy in some studies. rs6814664 tags an independent intronic signal. Individuals carrying C alleles at both loci accumulate risk from two mechanistically distinct SLC2A9 sources — both should be examined to estimate total SLC2A9-attributed urate load.

With rs11942223 (SLC2A9 intronic, independent signal): rs11942223 is a second independent intronic SLC2A9 signal (LD with rs6814664 is partial but not complete). Carriers of risk alleles at both intronic loci have additive urate elevation and should consider more aggressive dietary restriction of fructose and purines.

With ABCG2 rs2231142 (Q141K): ABCG2 controls intestinal urate excretion while SLC2A9 controls renal reabsorption. C-allele carriers at rs6814664 who also carry the ABCG2 Q141K T allele face urate accumulation from two independent routes — impaired renal clearance and impaired gut excretion — substantially increasing gout risk.

With BMI: The interaction between SLC2A9 genotype and BMI is one of the better-replicated gene-environment interactions for serum urate. CC homozygotes who are overweight or obese face compounded risk beyond what either factor predicts alone; weight management has outsized benefit in this group.

In roughly one in five people of European descent — and nearly half of East Asians — the GSTT1 gene is completely absent¹¹ the GSTT1 gene is completely absent
GSTT1 was absent from 38% of the global population, with higher frequencies in Asian populations. Not mutated. Not damaged. Simply deleted from the genome entirely. This isn't a typo in your genetic code; it's a common polymorphism that eliminates an entire phase II detoxification enzyme²² eliminates an entire phase II detoxification enzyme
Homozygous deletion results in complete absence of enzyme activity.

GSTT1³³ GSTT1
glutathione S-transferase theta-1 belongs to a family of enzymes that conjugate glutathione to toxic compounds, making them water-soluble for elimination. While its relatives GSTM1 and GSTP1 handle a broad spectrum of toxins, GSTT1 has a narrower but critical substrate preference: industrial halogenated solvents⁴⁴ industrial halogenated solvents
dichloromethane, ethylene oxide, methyl bromide, and methyl chloride, certain environmental carcinogens, and reactive metabolites from alcohol and tobacco smoke.

Without functional GSTT1, you can't efficiently detoxify these compounds. They linger longer in tissues, increasing oxidative DNA damage⁵⁵ increasing oxidative DNA damage
GSTT1-null subjects showed 1.6-fold increase in genotoxicity from industrial exposures and creating a documented cancer risk that varies by exposure and ethnicity.

The Mechanism

GSTT1 is a phase II metabolizing enzyme⁶⁶ phase II metabolizing enzyme
constitutively expressed in liver, kidney, lung, and gastrointestinal tract that catalyzes the conjugation of reduced glutathione (GSH) to electrophilic substrates. The gene is located at 22q11.23⁷⁷ 22q11.23
chromosome 22, cytogenetic band 11.23, in a gene cluster with its paralogues GSTT2 and GSTT2B.

The null variant results from a complete deletion of the entire gene⁸⁸ complete deletion of the entire gene
deletion spans all five exons. Individuals inherit two copies (chromosomes), creating three possible states: both copies present (GSTT1-positive), one copy present (heterozygous), or both copies deleted (GSTT1-null). The deletion follows Mendelian intermediary inheritance⁹⁹ Mendelian intermediary inheritance
gene-dosage effect with doubled expression in two functional alleles, where heterozygotes have roughly 50% enzyme activity compared to homozygous wild-type.

In GSTT1-null individuals, substrates cannot be efficiently conjugated and eliminated¹⁰¹⁰ substrates cannot be efficiently conjugated and eliminated
unable to perform biotransformation of toxic products via glutathione conjugation, leading to accumulation in tissues and increased oxidative stress.

Important limitation: This SNP (rs71748309) is a tag SNP used to infer GSTT1 deletion status, not a direct measurement of gene copy number. 23andMe does not reliably detect gene deletions¹¹¹¹ 23andMe does not reliably detect gene deletions
SNPs used to assess GSTT1 variants were not available on v5 chip; detection accuracy is uncertain. Results should be interpreted with caution and confirmed with specialized testing if clinically important.

The Evidence

GSTT1 null status has been extensively studied across dozens of cancer types and populations. The most consistent associations emerge from large meta-analyses¹²¹² large meta-analyses
combined evidence from 117+ studies totaling over 60,000 subjects:

Urinary system cancers: A meta-analysis of 117 studies¹³¹³ meta-analysis of 117 studies
26,666 cases, 37,210 controls found GSTT1 null genotype significantly increases risk (OR=1.13, 95% CI=1.05-1.22), with stronger effects for bladder cancer (OR=1.13) and prostate cancer (OR=1.14), particularly in Caucasians (OR=1.16) and Indians (OR=2.05).

Lung cancer: Among Asian populations, a meta-analysis of 23 studies¹⁴¹⁴ Asian populations, a meta-analysis of 23 studies
4,065 cases, 5,390 controls showed OR=1.28 (95% CI=1.10-1.49) for overall lung cancer risk. The effect was dramatically amplified in smokers: OR=1.94 (95% CI=1.27-2.96) for ever-smokers with GSTT1 null. Gene-environment interaction¹⁵¹⁵ Gene-environment interaction
heavy smokers (>60 pack-years) with GSTT1 null had OR=158.49.

Colorectal cancer: Pooled analysis of 46 case-control studies¹⁶¹⁶ Pooled analysis of 46 case-control studies
overall OR=1.21, 95% CI=1.10-1.33 showed increased risk in both Asians and Caucasians, with stronger association for rectal cancer (OR=1.13).

Breast cancer: Results vary by population. Chinese population meta-analysis¹⁷¹⁷ Chinese population meta-analysis
OR=1.31, 95% CI=1.02-1.67, though other studies show weaker or null associations. Asian-focused meta-analysis¹⁸¹⁸ Asian-focused meta-analysis
OR=1.19, 95% CI=1.01-1.41.

Alcohol metabolism: GSTT1 null genotype increases oxidative stress from alcohol¹⁹¹⁹ increases oxidative stress from alcohol
reactive oxygen species accumulate when GSTT1 is absent, contributing to liver disease risk in chronic drinkers. The enzyme helps detoxify acetaldehyde-derived reactive metabolites.

Chemotherapy toxicity: GSTT1 null individuals show higher risk of severe gastrointestinal toxicity²⁰²⁰ higher risk of severe gastrointestinal toxicity
from chemoradiation therapy in cervical cancer and increased drug-induced liver injury risk²¹²¹ increased drug-induced liver injury risk
PharmGKB very important pharmacogene designation.

Evidence level is strong for urinary and lung cancers, moderate for colorectal and breast cancers. The gene-environment interactions with smoking, occupational solvent exposure, and alcohol are well-established.

Practical Actions

If you carry the GSTT1 null genotype, you lack a specialized detoxification pathway. Compensation requires reducing substrate exposure²²²² reducing substrate exposure
minimize halogenated solvents, smoking, and heavy alcohol and supporting alternative glutathione-dependent pathways.

Avoidance strategies: Minimize exposure to GSTT1-specific substrates²³²³ GSTT1-specific substrates
dichloromethane in paint strippers, ethylene oxide in sterilization, halomethanes in chlorinated water. If you smoke, quitting is especially critical — the interaction between tobacco and GSTT1 null multiplies cancer risk²⁴²⁴ the interaction between tobacco and GSTT1 null multiplies cancer risk
OR increases from 1.28 baseline to 1.94 in smokers. Limit alcohol intake to reduce acetaldehyde burden.

Glutathione support: Cruciferous vegetables²⁵²⁵ Cruciferous vegetables
broccoli, Brussels sprouts, cabbage, kale are rich in glutathione precursors and upregulate remaining GST enzymes²⁶²⁶ upregulate remaining GST enzymes
isothiocyanates induce compensatory GST activity. However, effectiveness varies by genotype²⁷²⁷ varies by genotype
GSTT1 null individuals may have blunted response to cruciferous induction.

Antioxidant support: Alpha-lipoic acid regenerates oxidized glutathione²⁸²⁸ Alpha-lipoic acid regenerates oxidized glutathione
enhances intracellular and extracellular glutathione concentrations. Selenium supports glutathione recycling²⁹²⁹ Selenium supports glutathione recycling
key cofactor for glutathione peroxidase. N-acetylcysteine (NAC) provides cysteine³⁰³⁰ N-acetylcysteine (NAC) provides cysteine
rate-limiting precursor for glutathione synthesis.

Medical monitoring: Consider more frequent cancer screening³¹³¹ cancer screening
especially for urinary tract and lung if you have additional risk factors (smoking history, occupational exposures). Discuss GSTT1 status with your oncologist if undergoing chemotherapy — certain regimens carry higher toxicity risk³²³² certain regimens carry higher toxicity risk
drug-induced liver injury.

Interactions

GSTT1 doesn't operate alone. The glutathione S-transferase superfamily includes GSTM1 (rs1138272) and GSTP1 (rs1695), all working in concert to detoxify environmental toxins. Combined null genotypes amplify risk³³³³ Combined null genotypes amplify risk
dual GSTM1/GSTT1 null increases prostate cancer OR.

Oxidative stress defense: GSTT1 interacts with other antioxidant genes including SOD2 (rs4880) and GPX1 (rs1050450)³⁴³⁴ SOD2 (rs4880) and GPX1 (rs1050450)
combined polymorphisms increase oxidative damage. Genetic risk scores combining these variants³⁵³⁵ Genetic risk scores combining these variants
five-risk-genotype combinations increased metabolic syndrome risk.

Methylation pathway: Glutathione synthesis requires homocysteine-to-cysteine conversion³⁶³⁶ homocysteine-to-cysteine conversion
via the transsulfuration pathway. MTHFR variants (rs1801133, rs1801131) that elevate homocysteine may reduce glutathione availability³⁷³⁷ elevate homocysteine may reduce glutathione availability
MTHFR and GST polymorphisms studied together in oxidative stress conditions.

Smoking interaction: The multiplicative effect of smoking with GSTT1 null³⁸³⁸ multiplicative effect of smoking with GSTT1 null
lung cancer OR=158.49 for heavy smokers represents one of the strongest gene-environment interactions in cancer epidemiology. Similarly, occupational solvent exposure in GSTT1 null individuals³⁹³⁹ occupational solvent exposure in GSTT1 null individuals
increased risk of chronic toxic encephalopathy.

Cruciferous vegetable response: Effectiveness of dietary detox support varies by GST genotype⁴⁰⁴⁰ varies by GST genotype
GSTT1-null individuals may have altered response to isothiocyanates, though cruciferous intake still provides glutathione precursors⁴¹⁴¹ cruciferous intake still provides glutathione precursors
even without enzyme induction.

Proposed compound actions for supervisor review:

1. GSTT1 null + GSTM1 null (dual null genotype)

• Genotypes: rs71748309 DD + rs1138272 DD (or equivalent GSTM1 deletion marker)
• Combined effect: Complete loss of both theta and mu GST classes, severely compromising phase II detoxification
• Evidence: OR for lung cancer increases to 8.25 with dual deletion (PMID: 18463401)
• Recommendation: Strict avoidance of industrial solvents, smoking cessation mandatory, high-dose glutathione support (NAC 600mg twice daily, liposomal glutathione 500mg, alpha-lipoic acid 600mg), quarterly liver function monitoring
• Evidence level: strong
• Action type: lifestyle + supplement + monitoring

2. GSTT1 null + GSTP1 Ile105Val (rs1695 AG/GG)

• Genotypes: rs71748309 DD + rs1695 AG or GG
• Combined effect: Loss of GSTT1 plus reduced GSTP1 activity creates broad detoxification impairment
• Evidence: Elevated risk for prostate cancer and chemotherapy toxicity (PMID: 17707637)
• Recommendation: Enhanced cruciferous vegetable intake (3+ servings daily) to upregulate remaining GSTP1, avoid pesticides and herbicides, comprehensive antioxidant support
• Evidence level: moderate
• Action type: diet + avoidance

3. GSTT1 null + heavy smoking exposure

• Genotypes: rs71748309 DD + current or former smoker (>10 pack-years)
• Combined effect: Multiplicative cancer risk — lung cancer OR increases from 1.28 to 158.49 for heavy smokers
• Evidence: Multiple meta-analyses (PMID: 23637998, 15105047)
• Recommendation: Smoking cessation is non-negotiable, annual low-dose CT lung cancer screening starting age 50, NAC 1200mg daily for ex-smokers
• Evidence level: established
• Action type: avoidance + monitoring

4. GSTT1 null + MTHFR C677T homozygous (rs1801133 AA)

• Genotypes: rs71748309 DD + rs1801133 AA
• Combined effect: Impaired methylation reduces glutathione synthesis (homocysteine can't efficiently convert to cysteine)
• Evidence: GST and MTHFR polymorphisms studied together in oxidative stress (PMID: 24339523)
• Recommendation: Methylated B-vitamin complex (methylfolate 800mcg, methylB12 1000mcg, B6 50mg), NAC 600mg twice daily to bypass transsulfuration bottleneck
• Evidence level: moderate
• Action type: supplement

5. GSTT1 null + SOD2 Ala16Val (rs4880 GG)

• Genotypes: rs71748309 DD + rs4880 GG
• Combined effect: Reduced mitochondrial superoxide dismutase plus absent GSTT1 increases oxidative damage
• Evidence: Combined polymorphisms increase metabolic syndrome risk (PMID: 31396447)
• Recommendation: Mitochondrial antioxidant stack (CoQ10 200mg ubiquinol, alpha-lipoic acid 600mg, selenium 200mcg), reduce environmental oxidant exposure
• Evidence level: moderate
• Action type: supplement + lifestyle

BTBD9 encodes a BTB/POZ domain-containing protein¹¹ BTB/POZ domain-containing protein
A protein scaffold that bridges substrates to the CUL3-RBX1 E3 ubiquitin ligase complex, marking target proteins for proteasomal degradation that controls how quickly certain proteins are cleared from cells. In the brain, BTBD9 appears to regulate iron homeostasis in dopaminergic pathways — the same system responsible for dopamine signalling in motor circuits and the rest-activity cycle. This makes BTBD9 the molecular bridge between two seemingly unrelated complaints: difficulty falling asleep, and an irresistible urge to move the legs at rest.

The rs9394502 variant sits in an intron of BTBD9 and acts as a tag SNP²² tag SNP
A marker in strong linkage disequilibrium with one or more functional variants; it travels with the causal allele through generations even if it isn't causal itself for the risk haplotype. People carrying one or two T alleles show measurably higher rates of insomnia and restless legs syndrome in some of the largest genetic studies ever conducted.

The Mechanism

BTBD9 functions as a substrate adaptor for the CUL3-based E3 ubiquitin ligase complex, targeting specific proteins for proteasomal degradation. In Drosophila, loss-of-function models of the BTBD9 homologue produce periodic leg movements and reduced dopamine levels — the core features of RLS — suggesting the protein controls dopamine turnover in motor circuits.

The iron connection is direct: iron is a required cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. BTBD9 polymorphisms are significantly associated with serum ferritin levels in population studies, indicating that the protein influences systemic iron storage or turnover. When BTBD9 function is perturbed, iron homeostasis shifts, dopamine synthesis capacity falls, and the sensorimotor circuits controlling limb movements at rest become dysregulated — producing the classic RLS symptoms that are worst at night, when dopamine levels naturally dip to their daily minimum.

Insomnia and RLS share this biological substrate: both worsen when brain iron is low, both respond to iron repletion when ferritin is deficient, and both are enriched among carriers of BTBD9 risk variants.

The Evidence

The insomnia association was established at genome-wide significance by Jansen et al. 2019³³ Jansen et al. 2019
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nat Genet, 2019;51:394-403. In 1,331,010 individuals — one of the largest psychiatric GWAS at the time — rs9394502 reached p=8×10⁻¹⁸ with an odds ratio of 1.056 (95% CI 1.04–1.07). The modest per-allele effect size (5.6% increased odds per T allele) is typical for common polygenic risk variants; the significance is extraordinary because the sample is enormous.

The finding was independently replicated by Watanabe et al. 2022⁴⁴ Watanabe et al. 2022
Watanabe K et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nat Genet, 2022;54:1125-1132 in an even larger meta-analysis (593,724 cases, 1,771,286 controls), where rs9394502 surpassed p=4×10⁻²⁰ — five orders of magnitude below the genome-wide significance threshold.

BTBD9's role in restless legs syndrome was established earlier. Winkelmann et al. 2007⁵⁵ Winkelmann et al. 2007
Winkelmann J et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet, 2007;39:1000-6 reported BTBD9 as one of three genome-wide significant RLS loci, with each risk variant conferring more than 50% increased risk for RLS. Subsequent studies confirmed that BTBD9 risk alleles also associate with periodic limb movements of sleep (PLMS), a closely related motor phenotype that disrupts sleep architecture even when the person is unaware of it.

Practical Actions

For T allele carriers — particularly TT homozygotes — the most directly actionable intervention is iron status assessment. Clinical guidelines for RLS recommend checking serum ferritin and targeting levels above 75 ng/mL (some guidelines recommend 100 ng/mL) because brain iron deficiency drives symptoms even when hemoglobin is normal. This is a genotype-specific monitoring threshold: the general population guideline for iron deficiency (ferritin <12 ng/mL) dramatically underestimates the brain iron requirement in susceptible individuals.

For TT carriers with confirmed RLS, oral ferrous sulfate (325 mg every other day on an empty stomach) is the standard first-line approach when ferritin is below 75 ng/mL. For those who cannot tolerate oral iron or have malabsorption, intravenous ferric carboxymaltose produces faster and more sustained ferritin rises.

Interactions

The BTBD9 risk haplotype shows strongest effect when combined with other RLS-associated variants. rs3923809 (also in BTBD9) is in partial linkage disequilibrium with rs9394502; carriers of both risk alleles show stronger periodic limb movement severity. MEIS1 rs2300478 on chromosome 2p encodes a transcription factor in the same developmental pathway as BTBD9 and independently triples RLS risk — combined MEIS1 + BTBD9 risk genotypes are found in a substantial fraction of diagnosed RLS patients. MAP2K5 rs6494696 represents a third independent RLS locus identified in the same 2007 GWAS. Each locus acts additively; the compound risk from multiple BTBD9 + MEIS1 + MAP2K5 risk genotypes is an active area of research and a natural candidate for compound action entries.

When the GABRIEL Consortium published the largest asthma genome-wide association study of its era in 2010, one of the five genome-wide significant signals landed squarely on chromosome 2q12 — a dense cluster of interleukin-1 receptor family genes including IL1RL1 (ST2)¹¹ IL1RL1 (ST2)
The receptor for IL-33; encodes the ST2 protein that triggers type 2 immune responses when bound by the alarmin cytokine IL-33 and IL18R1²² IL18R1
Encodes the IL-18 receptor subunit 1, which partners with IL18RAP to form the functional IL-18 receptor complex. rs3771166 is the lead tag SNP for this locus, sitting within an intron of IL18R1 approximately 17 kb downstream of IL1RL1.

The Mechanism

rs3771166 is an intronic variant in IL18R1 that acts as a tag for regulatory variation across the entire IL1RL1/IL18R1/IL18RAP gene cluster. The 2q12.1 locus is a tightly packed receptor family cluster in which multiple variants are in partial linkage disequilibrium with one another. The G risk allele at rs3771166 captures the cumulative regulatory signal affecting expression of both IL18R1 (the IL-18 receptor) and nearby IL1RL1 (the IL-33 receptor / ST2). IL-18 and IL-33 are distinct but complementary alarmins³³ alarmins
Damage-associated cytokines released by stressed or dying epithelial cells; they activate innate immune sentinels without requiring pathogen-specific recognition that coordinate early type 2 immune activation. IL-18 can promote both Th1 responses (with IL-12) and amplify Th2/ILC2 responses (without IL-12), making IL18R1 expression a context-dependent modulator of airway inflammation magnitude.

The Evidence

Moffatt et al. (NEJM, 2010)⁴⁴ Moffatt et al. (NEJM, 2010)
A large-scale, consortium-based genomewide association study of asthma. NEJM 363:1211–1221 established rs3771166 as the lead signal at 2q12 with p=3×10⁻⁹ in 10,365 asthma cases and 16,110 controls, making it one of only five loci to reach genome-wide significance in what was then the largest asthma GWAS. The G allele confers an odds ratio of approximately 1.15 per copy (95% CI 1.10–1.20), placing it in the moderate-effect range typical of complex disease susceptibility variants.

The finding replicated across ancestry groups. Torgerson et al. (Nature Genetics, 2011)⁵⁵ Torgerson et al. (Nature Genetics, 2011)
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations confirmed the IL1RL1 locus in European American, African American, and Latino cohorts, demonstrating that this signal is not population-specific. Wan et al. (Thorax, 2012)⁶⁶ Wan et al. (Thorax, 2012)
Genome-wide association study to identify genetic determinants of severe asthma extended the finding to severe asthma specifically, with the 2q12 locus achieving p=5.59×10⁻⁸.

Savenije et al. (JACI, 2014)⁷⁷ Savenije et al. (JACI, 2014)
Association of IL33-IL1RL1 pathway polymorphisms with wheezing phenotypes in childhood showed that different variants within this locus associate with distinct wheezing trajectories in birth cohorts — late-onset wheeze maps specifically to IL1RL1 variants, highlighting how functional heterogeneity within the cluster shapes disease phenotype.

Practical Actions

The G allele at rs3771166 modestly elevates asthma and atopic airway disease risk, operating through the shared IL-18R/ST2 signaling axis. While rs3771166 itself is a tag SNP (its effect is attributed to regulatory changes across the locus rather than a direct protein change), the downstream consequences are identical to other variants in the cluster: reduced threshold for IL-33- and IL-18-driven type 2 airway inflammation.

G risk allele carriers benefit from early-warning monitoring of eosinophil counts, which reflect active type 2 inflammation through this pathway. For AG heterozygotes, standard monitoring suffices. For GG homozygotes — who carry the full additive genetic load at this locus — proactive lung function surveillance and early escalation of asthma treatment are well-supported by the evidence.

Interactions

rs3771166 is part of the same chromosomal locus as rs1420101 (the primary IL1RL1 eQTL for sST2 decoy receptor levels). These SNPs tag partially overlapping but potentially independent signals within the 2q12.1 cluster. Carrying risk alleles at both rs3771166 and rs1420101 may confer additive susceptibility, as each tags different functional elements within the IL1RL1/IL18R1/IL18RAP regulatory architecture.

The upstream IL33 gene variants rs992969 and rs1342326 are pathway partners: they increase IL-33 ligand production, which must then be buffered by the ST2/sST2 system partly regulated by this locus. Individuals with risk alleles across multiple nodes of the IL-33/ST2 axis (ligand, receptor, decoy) accumulate additive susceptibility.

CYP3A4 is the most important drug-metabolizing enzyme in the human body, responsible for the first-pass and systemic clearance of approximately 50% of all prescribed medications. When you swallow a statin, an immunosuppressant, or a benzodiazepine, CYP3A4 in your liver and intestinal wall is the primary enzyme that breaks it down before it reaches your bloodstream. A genetic variant that impairs this enzyme — even modestly — can therefore have significant consequences for how drugs behave in your body.

rs55785340, also known as CYP3A4*2, is a missense variant¹¹ missense variant
A mutation that changes a single amino acid in the protein sequence that substitutes proline for serine at position 222 of the CYP3A4 protein (p.Ser222Pro). It is rare globally — found almost exclusively in Europeans at an allele frequency of roughly 0.07% in large population databases — but its functional impact on nifedipine metabolism is well-documented in vitro, and a large pharmacokinetic study has now confirmed its clinical relevance for statin dosing.

The Mechanism

CYP3A4 catalyzes oxidative reactions by threading drug molecules into its active site, where an oxygen atom is transferred. Serine 222 sits in a substrate-recognition region of the enzyme. The Ser222Pro substitution replaces a flexible serine residue with a rigid proline, which is known to restrict backbone flexibility and alter local protein conformation. The resulting structural change affects how well the enzyme binds and processes certain substrates.

The original characterization by Sata et al. (2000)²² Sata et al. (2000)
Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12. Clin Pharmacol Ther 67:48-56 expressed the CYP3A4*2 enzyme in baculovirus and directly measured catalytic activity. The key finding was substrate-dependent impairment³³ substrate-dependent impairment
The CYP3A4*2 variant is a partial loss-of-function, not a complete null — its effect differs depending on which drug enters the active site: nifedipine oxidation showed reduced intrinsic clearance compared to wild-type, while testosterone 6β-hydroxylation was not significantly different. This substrate selectivity matters clinically because it means some CYP3A4 drugs are more affected than others.

The Evidence

The most clinically relevant evidence comes from a genomewide association study of simvastatin pharmacokinetics⁴⁴ genomewide association study of simvastatin pharmacokinetics
Mykkänen AJH et al. Genomewide Association Study of Simvastatin Pharmacokinetics. Clin Pharmacol Ther 2022;112(3):676-686 in 229 Finnish volunteers. Carriers of CYP3A4*2 or CYP3A4*22 (the more common *22 splice variant) showed 87% (90% CI, 39–152%) larger simvastatin acid AUC⁵⁵ AUC
Area under the concentration-time curve, the standard pharmacokinetic measure of total drug exposure than normal metabolizers (P=6.4×10⁻⁴). Because the study grouped *2 and *22 carriers together as "intermediate CYP3A4 metabolizers," the effect size specifically attributable to *2 is not isolated, but the direction is clear: heterozygous carriers are exposed to substantially more simvastatin acid per dose.

The mechanism explains this finding: simvastatin (as the acid form) is a CYP3A4 substrate, and with reduced enzyme activity, less drug is cleared on first pass through the intestinal wall and liver. The result is higher plasma concentrations per dose — the same pharmacokinetic principle that underlies the dangerous interactions between statins and CYP3A4 inhibitors like clarithromycin or grapefruit juice.

Population data from ExAC and 1000 Genomes⁶⁶ ExAC and 1000 Genomes
Large-scale sequencing consortia aggregating hundreds of thousands of samples confirms the variant is nearly absent outside European populations. Of 121,010 alleles in ExAC, only 104 carried the G allele (0.086%), and all occurrences were in non-African, non-East-Asian participants. The FINRISK Finnish cohort showed a slightly higher rate (~1%), consistent with population-specific enrichment in Northern Europe.

Practical Actions

For carriers of CYP3A4*2, the most directly actionable implication is statin safety. Statins metabolized by CYP3A4 — primarily simvastatin, lovastatin, and atorvastatin — will reach higher plasma concentrations per dose. High statin exposure raises the risk of myopathy and rhabdomyolysis⁷⁷ myopathy and rhabdomyolysis
Muscle inflammation and, in severe cases, breakdown of muscle tissue that can cause kidney failure (1-in-10,000 risk with standard doses). Pravastatin, rosuvastatin, and fluvastatin are largely independent of CYP3A4 and are not affected by this variant.

For immunosuppressants (tacrolimus, cyclosporine) after organ transplantation, reduced CYP3A4 activity would theoretically raise drug exposure and increase toxicity risk. However, because CYP3A4*2 is so rare, clinical guidelines have not been developed for it specifically — clinicians rely on therapeutic drug monitoring as standard of care for these drugs regardless of genotype.

There are currently no CPIC or DPWG guidelines specific to CYP3A4*2. Clinical pharmacogenomics testing panels that include CYP3A4 most commonly genotype for CYP3A4*22 (rs35599367) and CYP3A5*3 (rs776746), which are far more common and have established clinical utility. CYP3A4*2 is too rare for population-level clinical guidelines, but individual carriers benefit from genotype-aware prescribing.

Interactions

CYP3A4*2 can combine with CYP3A4*22 (rs35599367) or CYP3A5*3 (rs776746) on the other allele, producing compound genotypes with potentially greater reduction in total CYP3A enzyme activity. In a compound heterozygote carrying both CYP3A4*2 and CYP3A4*22 (one on each chromosome), overall CYP3A4 activity would be reduced from both alleles, yielding a predicted poor metabolizer phenotype for nifedipine- class substrates. This combination, while rare, would warrant extra caution with CYP3A4 substrates.

Environmental CYP3A4 inhibitors dramatically amplify the effect: grapefruit juice, clarithromycin, ketoconazole, and ritonavir can inhibit CYP3A4 by 3- to 8-fold. For a CYP3A4*2 carrier who already has baseline reduced clearance, adding a strong inhibitor compounds the exposure increase and significantly raises toxicity risk with narrow-therapeutic-index drugs.

Every time you form a new memory, a precise choreography of ion channels must activate in hippocampal neurons at the right moment. The CaV3.2 channel¹¹ CaV3.2 channel
T-type voltage-gated calcium channel encoded by CACNA1H; opens near the resting membrane potential, earning the "T" for transient and tiny currents is one of the key players in this process. Unlike the high-voltage-activated L-type channels that require strong depolarisation, T-type channels open with small, subthreshold voltage changes — making them ideally positioned to respond to weak synaptic inputs and gate whether those inputs are converted into durable synaptic changes. rs61734410 substitutes leucine for proline at position 640 in this channel, a region critical for channel gating. The change does not dramatically alter baseline channel function but reduces how the channel responds to certain modulating inputs, including pharmacological ones.

The Mechanism

Pro640 lies within the second intracellular loop of the CaV3.2 alpha-1H subunit, a domain involved in channel inactivation kinetics. The Pro640Leu substitution²² Pro640Leu substitution
proline is a structurally rigid amino acid that creates kinks in protein loops; replacing it with leucine, a flexible aliphatic residue, alters the loop's geometry and potentially the conformational transitions that control channel gating does not produce measurable differences in baseline CaV3.2 electrophysiology under standard conditions — current amplitude, activation voltage, and steady-state inactivation are unchanged. The variant's effect becomes detectable only when the channel is challenged: ethosuximide's ability to accelerate CaV3.2 inactivation (its core anti-epileptic mechanism) is significantly blunted for the Leu640 channel compared to wild-type Pro640.

Beyond pharmacodynamics, CaV3.2's role in cognition is well established at the channel level. CaV3.2 knockout mice show shortened LTP duration — 120 minutes versus 180 minutes in wild-type controls³³ shortened LTP duration — 120 minutes versus 180 minutes in wild-type controls
Chen et al. 2012, PLoS One; LTP = long-term potentiation, the cellular correlate of memory formation; shorter LTP means synaptic changes are less durable and impaired retrieval of context-associated memory without deficits in spatial learning. A separate study documented that CaV3.2-deficient mice fail novel object and spatial object recognition tasks with high statistical significance ⁴⁴ Gangarossa et al. 2014, Frontiers in Behavioral Neuroscience; novel object recognition p<0.001 compared to wild-type controls.

T-type calcium channels at synapses contribute to plasticity through a distinct mechanism: they activate at subthreshold potentials, driving calcium influx that can interact cooperatively with NMDA receptor signalling to lower the threshold for LTP induction. Nicholson & Kullmann 2017⁵⁵ Nicholson & Kullmann 2017
Journal of Physiology; demonstrated T-type channel- dependent, NMDA receptor-independent LTP in hippocampal interneurons showed that blocking T-type channels prevents LTP even when the standard NMDA receptor-dependent pathway is intact, establishing T-type channels as an independent gateway to synaptic strengthening.

The Evidence

Direct evidence for Pro640Leu and cognitive outcomes is limited — the variant has not been individually studied in human cognitive GWAS datasets at genome-wide significance. The biological evidence rests on the channel-level studies above and a pharmacogenetics finding: in a childhood absence epilepsy cohort, the Pro640Leu genotype was associated with higher odds of failing to achieve seizure-freedom on ethosuximide ⁶⁶ Glauser et al. 2017, Annals of Neurology; OR 2.63; n=81 patients; in vitro electrophysiology confirmed blunted drug effect at Leu640 channel. A separate replication study found no significant association in a smaller cohort (n=62), highlighting the moderate and still-contested nature of this pharmacogenetic claim.

At the population level, a case-control study ⁷⁷ Wang et al. 2024, Molecular Genetics & Genomic Medicine; 226 migraineurs vs 452 controls; ORadj 1.56, 95% CI 1.07-2.28 for CT genotype found the heterozygous CT genotype to be associated with migraine risk, consistent with CaV3.2's role in trigeminovascular pain signalling and cortical excitability. The ClinVar classification of this variant is Benign (multiple submitters, no conflicts), reflecting that it does not cause monogenic disease — the associations are probabilistic and polygenic.

Practical Actions

For CT and TT carriers, the most evidence-based intervention addresses the channel's known modulation by divalent cations. Magnesium is a natural blocker of T-type calcium channels — it competes with calcium at the channel pore and modulates gating through surface charge screening. This is the same class of action that gives magnesium its anti-migraine benefit in clinical trials. Supplementing magnesium glycinate or threonate supports this channel-level modulation while also providing general neurological benefits through NMDA receptor regulation.

DHA (docosahexaenoic acid) incorporates into neuronal membrane phospholipids and maintains the membrane fluidity required for optimal ion channel conformational dynamics. Membranes depleted in DHA are more rigid, altering the voltage- sensing properties of embedded channels including T-type calcium channels. For TT carriers facing the greatest Leu640 channel dosage, ensuring adequate DHA intake supports the membrane environment in which CaV3.2 operates.

If you or a family member carry this variant and are being treated for childhood absence epilepsy with ethosuximide, the pharmacogenetics data provide a rationale for discussing alternative or adjunctive agents with a neurologist, as the Leu640 channel shows reduced pharmacodynamic sensitivity to ethosuximide's mechanism.

Interactions

CaV3.2 operates in concert with the broader T-type channel family: CaV3.1 (CACNA1G) and CaV3.3 (CACNA1I) are expressed in overlapping brain regions and can partially compensate for CaV3.2 deficiency in some circuits. Variants in CACNA1A (rs10405121), which encodes the P/Q-type CaV2.1 channel dominant in cerebellar and cortical neurons, represent a distinct calcium channel pathway but converge on similar migraine and neurocognitive phenotypes. The migraine risk from rs61734410 is expected to be additive with TRPM8 locus risk (rs10166942), which operates through a separate cold-pain threshold mechanism.

Your kidneys filter roughly 700 mg of uric acid per day, and the dominant genetic determinant of how efficiently they do so is the SLC2A9 gene. Most people have heard of gout as a dietary problem — too much red meat, too much beer — and diet does matter. But for individuals carrying risk variants at SLC2A9, the kidneys are genetically programmed to reabsorb more urate back into the bloodstream than they should, regardless of diet.

rs6815001 is an [intronic variant | a variant in the non-coding region within a gene, which typically influences gene expression, splicing, or regulatory element function rather than directly changing the protein sequence] within SLC2A9 that tags an independently acting haplotype affecting renal urate clearance. It is a statistically independent signal from the well-characterized Arg265His missense variant (rs3733591), meaning that it captures different genetic architecture at this locus — distinct combinations of regulatory variants in linkage disequilibrium that influence how much GLUT9 is expressed or how the two protein isoforms are balanced.

The Mechanism

SLC2A9 encodes GLUT9¹¹ GLUT9
Glucose Transporter 9 — despite its name, GLUT9 transports urate with far higher affinity than glucose in the kidney proximal tubule, the major renal urate transporter. GLUT9 exists in two isoforms: the long isoform (GLUT9a) localizes to the basolateral membrane of proximal tubule cells and mediates urate reabsorption from the tubular interstitium back into the bloodstream; the short isoform (GLUT9b) sits on the apical membrane and handles secretion into the tubular lumen. The net balance of these two activities determines how much urate your kidneys retain versus excrete.

Intronic variants in SLC2A9 like rs6815001 influence urate levels through regulatory mechanisms — altering transcription factor binding, changing the ratio of GLUT9a to GLUT9b expression, or modifying splice site usage. Fine-mapping studies of the SLC2A9 locus have identified at least five independent marginal effects and three epistatic SNP pairs in the 4p16.1 region (Wei et al., 2014)²² (Wei et al., 2014), with the rs6815001 haplotype representing one of these statistically separable signals. The G allele at rs6815001 tags a haplotype associated with less efficient net urate excretion, while the C allele tags a haplotype that supports more favorable urate clearance.

The fructose connection adds another dimension: GLUT9 also transports fructose, and fructose metabolism generates urate through AMP catabolism. High fructose intake therefore amplifies the effect of G-allele haplotypes, because both dietary urate precursors and impaired renal clearance push serum urate upward simultaneously.

The Evidence

SLC2A9 as the dominant urate locus: The SLC2A9 locus was first identified as a urate determinant in 2008 through parallel GWAS in Croatian and German populations, with intronic variants accounting for 1.7–5.3% of serum uric acid variance — the largest single-locus effect known for a quantitative trait in humans (Vitart et al., 2008)³³ (Vitart et al., 2008).

Multiple independent signals at SLC2A9: Conditional analysis consistently reveals that a single lead SNP does not capture all the genetic information at this locus. In African-ancestry populations, conditional analysis identified a second independent signal (p = 5.75 × 10⁻¹⁷ after conditioning on the primary signal), demonstrating that multiple causal or tagging variants act through separable mechanisms (Chen et al., 2020)⁴⁴ (Chen et al., 2020). Regional fine-mapping of 4p16.1 found five independent marginal effects plus epistatic interactions between SNP pairs, together explaining 1.5% more urate variance than the lead SNP alone (Wei et al., 2014)⁵⁵ (Wei et al., 2014).

Sex-specific amplification: SLC2A9 variants overall have disproportionately larger effects in women than in men: they explain 3.4–8.8% of urate variance in women versus 0.5–2.0% in men (Dalbeth et al., 2015)⁶⁶ (Dalbeth et al., 2015). Estrogen independently promotes renal urate excretion, so pre-menopausal women carrying risk alleles may have partially attenuated effects. Post-menopausal women lose this buffering and become more vulnerable to genetically elevated uric acid.

Metabolic syndrome amplification: Insulin resistance independently impairs renal urate excretion. Individuals carrying SLC2A9 risk haplotypes and also having metabolic syndrome experience substantially higher gout risk (OR ~1.39) compared to those with genetic risk alone, establishing a gene-environment interaction that makes metabolic health a key modifiable target for SLC2A9 risk carriers.

Practical Actions

The G allele at rs6815001 tags a haplotype that contributes to elevated serum uric acid through impaired renal clearance. Since this is a regulatory effect (not a missense change in the transporter itself), the magnitude is expected to be smaller per allele than the Arg265His missense variant, but it compounds when both signals are unfavorable. Dietary and lifestyle changes that support renal urate excretion are the evidence-based first line.

The uric acid threshold that matters is 6.8 mg/dL — this is the saturation point for monosodium urate crystal formation in synovial fluid at body temperature. Keeping serum urate below 6 mg/dL provides a meaningful safety margin. Dietary purines (organ meats, red meat, shellfish), alcohol (especially beer), and fructose-sweetened beverages each raise serum urate by 0.3–1.0 mg/dL and are modifiable targets. Conversely, low-fat dairy, coffee, and vitamin C have evidence for modest uric acid reduction and can serve as genotype-aware substitutions.

Interactions

rs6815001 and rs3733591 (Arg265His): These two SLC2A9 variants are statistically independent (low linkage disequilibrium), meaning a person can carry risk alleles at both simultaneously. Individuals who carry the G allele at rs6815001 and the C allele at rs3733591 carry additive risk from two distinct SLC2A9 mechanisms — one regulatory (rs6815001) and one functional/missense (rs3733591). The combination should be considered when counseling about gout prevention intensity.

rs6815001 and ABCG2 rs2231142: ABCG2 mediates intestinal urate secretion while SLC2A9 mediates renal reabsorption — independent pathways. Risk alleles at both loci produce additive serum urate elevation substantially greater than either alone, and in combination with metabolic syndrome push mean uric acid well above the hyperuricemia threshold even in otherwise healthy adults.

Fructose and sugar-sweetened beverages: High fructose intake generates urate through AMP catabolism and also competes with urate for renal excretion. For G-allele carriers already dealing with impaired renal clearance, high fructose intake provides a second independent driver of urate accumulation, making fructose reduction a particularly high-yield dietary target.

PEMT (phosphatidylethanolamine N-methyltransferase) is an enzyme in the liver that produces phosphatidylcholine ¹¹ A major component of cell membranes and bile, essential for fat transport from the liver (PC) from phosphatidylethanolamine using three sequential methylation reactions. Phosphatidylcholine is a critical component of cell membranes, bile (needed for fat digestion), and VLDL particles (which transport fat from the liver). PEMT is the body's primary internal source of choline, reducing dependence on dietary intake.

The Mechanism

The Val175Met variant ²² Valine-to-methionine substitution at position 175 of the protein (p.Val175Met) (rs7946) substitutes valine with methionine at position 175 of the PEMT protein. The T allele (Met) reduces enzyme activity by approximately 30%, meaning less phosphatidylcholine is produced internally. This shifts the burden to dietary choline sources. Each methylation reaction requires one S-adenosylmethionine (SAM) ³³ SAM is the body's universal methyl donor molecule, so PEMT activity is also dependent on overall methylation capacity. Notably, the T allele is very common in Europeans (75% frequency) but much rarer in East Asians (24%).

The Gender Dimension

PEMT is an estrogen-responsive gene — estrogen upregulates its expression. This means premenopausal women with PEMT variants may be partially protected by their estrogen levels. However, postmenopausal women with PEMT variants face a particularly high risk of choline deficiency because they lose both the genetic capacity and the hormonal support for internal choline production.

The Evidence

A clinical trial at UNC Chapel Hill⁴⁴ A clinical trial at UNC Chapel Hill
da Costa KA et al. FASEB J 2006 — common genetic polymorphisms affect the human requirement for the nutrient choline demonstrated that women with PEMT variants who consumed a low-choline diet developed liver dysfunction (fatty liver, elevated liver enzymes) significantly more often than women without the variant. A Japanese study⁵⁵ Japanese study
Song J et al. PEMT Val175Met and NASH susceptibility, 2007 confirmed that the variant is significantly more frequent in NASH patients. More recent research shows sex-specific effects⁶⁶ sex-specific effects
PEMT rs7946 polymorphism and sex modify choline effect on hepatic steatosis risk, 2023 where adequate dietary choline intake modifies the risk of hepatic steatosis differently in men and women.

Practical Implications

Egg yolks are the most practical dietary source of choline (about 150mg per yolk). Liver is even richer but less commonly consumed. If you carry the T allele, deliberately including choline-rich foods daily is one of the simplest and most impactful dietary strategies informed by your genetics. This is especially important if you also have MTHFD1 variants (rs2236225), which independently increase choline needs.

Interactions

PEMT interacts with MTHFD1 (rs2236225) — both variants increase choline requirements, and the combined effect can be substantial. It also interacts with MTHFR (rs1801133), as PEMT activity depends on SAM from the methylation cycle.

Deep in the hypothalamus, a cluster of roughly 20,000 neurons called the suprachiasmatic nucleus (SCN)¹¹ suprachiasmatic nucleus (SCN)
The master pacemaker of the mammalian circadian clock. It sits directly above the optic chiasm and receives light signals from the retina to synchronize internal timing with the external day-night cycle orchestrates the timing of nearly every biological rhythm in the body. These neurons don't just keep time independently — they must continuously synchronize with each other to produce a coherent, high-amplitude rhythm capable of driving sleep-wake cycles, hormone secretion, and metabolism. Vasoactive intestinal peptide (VIP) is the primary signal responsible for that synchronization.

rs9479402 sits approximately 54 kilobases downstream of the VIP gene on chromosome 6. It is a regulatory variant — one of only seven chronotype GWAS hits that cluster near established circadian genes — identified because it influences how much morningness-promoting VIP signaling reaches the SCN's neuronal network. The C allele, which reduces effective VIP output in this regulatory context, predicts evening preference.

The Mechanism

VIP is released by a subset of SCN neurons called VIP neurons²² VIP neurons
Approximately 10% of SCN neurons that co-express VIP and the peptide PHI. They project widely within the SCN and are critical for coupling the individual cellular clocks into a unified tissue-level rhythm during the active phase of the circadian cycle. VIP binds to the VPAC2 receptor on neighboring SCN cells, activating adenylate cyclase, raising cAMP, and driving rhythmic gene expression through the CREB transcription factor. This paracrine signaling keeps the ~20,000 individual cellular clocks running in phase with each other.

The necessity of this coupling signal is dramatically illustrated in VIP-null mice: animals lacking VIP fragment into arrhythmic behavior within days of being placed in constant darkness, with individual SCN neurons drifting to different free-running periods instead of marching together. Weaker or less precisely timed VIP signaling — which the C allele at rs9479402 is thought to produce through altered regulatory output — results in a softer circadian amplitude and a tendency for the clock to drift toward later timing.

Because VIP signaling is also part of the SCN's response to zeitgebers³³ zeitgebers
External time cues (German: "time givers") that synchronize the internal circadian clock to the environment. The strongest is light, followed by meal timing, exercise, and social contact, reduced VIP output can impair the speed and completeness of re-synchronization after schedule disruptions — making jet lag recovery slower and shift-work adaptation more difficult.

The Evidence

Discovery GWAS. Hu et al. 2016⁴⁴ Hu et al. 2016
Hu Y et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nat Commun, 2016 conducted the first large-scale chronotype GWAS, identifying 15 genome-wide significant loci in 89,283 23andMe participants. rs9479402 near VIP was among seven hits at recognized circadian genes (P = 3.9 × 10⁻¹¹), establishing VIP as a human chronotype determinant and not merely a rodent pacemaker signal.

Replication and scale-up. Jones et al. 2016⁵⁵ Jones et al. 2016
Jones SE et al. Genome-wide association analyses in 128,266 individuals identifies new morningness and sleep duration loci. PLoS Genet, 2016 replicated and extended these findings in 128,266 UK Biobank participants, further confirming the VIP locus association with chronotype. The larger Jones et al. 2019⁶⁶ Jones et al. 2019
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat Commun, 2019 study — combining UK Biobank and 23andMe in 697,828 individuals — expanded the number of chronotype loci to 351 and confirmed VIP pathway enrichment. Activity-monitor data in 85,760 individuals showed that carrying the most morningness alleles shifts mean sleep timing 25 minutes earlier than carrying the fewest; the VIP locus contributes meaningfully to this polygenic gradient.

VIP-null animal models. Mice lacking VIP show nearly complete loss of behavioral circadian rhythmicity in constant conditions, with individual SCN neurons drifting to different free-running periods. This establishes VIP as a non-redundant coupling signal for the SCN network — not merely one of several parallel mechanisms. The human genetics finding that a regulatory variant near VIP shifts chronotype is mechanistically coherent with this animal literature.

Practical Actions

For C allele carriers, the primary implication is a biological pull toward later timing that requires active compensation through zeitgeber reinforcement. The SCN responds most strongly to bright morning light and the timing of first meals — these two signals, consistently applied, can partially overcome a weaker VIP-driven synchronization signal and shift the clock earlier.

The second implication is resilience: carriers may find it harder to recover from time-zone crossings or schedule changes, because the re-synchronization process relies on VIP-mediated coupling to propagate the light signal through the SCN network.

Interactions

VIP interacts most directly with the core clock genes PER2 (rs35333999) and CLOCK (rs1801260). VIP/VPAC2 signaling drives cAMP-CREB activation of Per1 transcription, directly feeding into the transcription-translation feedback loop that generates the ~24-hour period. Carrying evening-shift variants at both VIP (rs9479402 C) and CLOCK (rs1801260 G) would be expected to compound the delay, though the combined effect has not been formally quantified in humans. RASD1 (rs11545787), which gates light-driven phase shifts in the SCN, is a second pathway partner — both VIP coupling and light-gating act in series to determine how fast the SCN re-entrains to new schedules.

The IL-33/ST2 signaling axis sits at the center of allergic disease biology. IL-33, an alarmin cytokine¹¹ alarmin cytokine
A danger signal released from damaged epithelial cells in the airways, skin, and gut that activates type 2 immunity via mast cells, eosinophils, and ILC2 innate lymphoid cells released during allergen exposure or viral infections, binds the ST2 receptor encoded by IL1RL1 on chromosome 2. IL1RL1 also generates a second splice form — soluble sST2 — that floats in the bloodstream and acts as a decoy, intercepting IL-33 before it can activate immune cells. Most well-studied IL1RL1 variants alter the balance between membrane-bound ST2 and soluble sST2. rs3771175 occupies a distinct position in this regulatory landscape: a 3'-UTR variant that increases total IL1RL1 expression and, in a large Chinese Han case-control study, is associated with reduced susceptibility to allergic rhinitis.

The Mechanism

rs3771175 sits in the 3'-untranslated region (3'UTR) of IL1RL1 at chromosome 2 position 102,343,750 (GRCh38), a region that controls transcript stability and translational efficiency rather than protein coding sequence. The minor A allele functions as a cis-eQTL²² cis-eQTL
an expression quantitative trait locus — a genetic variant that controls how much RNA is produced from the nearby gene, rather than altering the protein structure: carriers of the A allele show increased IL1RL1/ST2 expression in whole blood cells, a finding that reached statistical significance (p = 0.03) in a cross-sectional study of 506 individuals. rs3771175 is in complete linkage disequilibrium³³ linkage disequilibrium
LD r² = 1.0 means these two variants always travel together through the population — detecting one allele perfectly predicts the other with rs17639215, suggesting that the two SNPs tag the same functional haplotype.

How increased IL1RL1 expression translates to reduced allergic rhinitis risk is not fully resolved by the available evidence, but the most plausible interpretation draws on the IL1RL1 splicing architecture: the gene's two promoters differentially drive the soluble sST2 isoform (from the distal promoter) versus the membrane-bound ST2L isoform (from the proximal promoter). A 3'UTR variant increasing overall expression — particularly from the distal promoter's transcript — would expand the pool of circulating sST2 decoy receptor, increasing the capacity to intercept IL-33 before it reaches membrane-bound ST2L on mast cells and eosinophils. This would mirror the protective mechanism of the rs1420101 C allele, which is also associated with higher sST2 levels.

The Evidence

The primary allergy-relevant evidence comes from Li et al. (J Clin Lab Anal, 2022)⁴⁴ Li et al. (J Clin Lab Anal, 2022)
Association between IL1RL1 gene polymorphisms and allergic rhinitis risk in the Chinese Han population; 1,000 AR patients vs 1,000 controls, a well-powered case-control study of 1,000 allergic rhinitis patients and 1,000 healthy controls in the Chinese Han population. The rs3771175 A allele was associated with significantly reduced AR risk across multiple genetic models: OR 0.76 (p = 0.032) for heterozygous carriers, OR 0.76 (p = 0.031) under the dominant model, and OR 0.79 (p = 0.039) on a log-additive scale. Genotype frequencies in the study were TT 86.5% in cases versus 83.0% in controls, reflecting the protective shift with each A allele. A stratified sex analysis revealed a substantially stronger protective effect in males: heterozygous OR 0.45 (p = 0.001), dominant model OR 0.44 (p = 0.001), log-additive OR 0.48 (p = 0.001). This sex-stratified finding is notable given the sex differences in allergic rhinitis prevalence and suggests the variant's protective effect may operate through androgen- or sex-hormone-modulated IL-33/ST2 signaling. After false-discovery rate correction across the three IL1RL1 SNPs simultaneously, the association did not survive correction (FDR p = 0.075), which limits the strength of the current evidence to moderate — meaningful but not yet replicated in independent atopic cohorts.

The eQTL relationship was independently established in a Brazilian cohort (Trindade et al. PLoS One, 2023)⁵⁵ (Trindade et al. PLoS One, 2023)
Single nucleotide variants in IL33 and IL1RL1 (ST2) genes are associated with periodontitis and with Aggregatibacter actinomycetemcomitans; n=506: homozygous A/A carriers showed significantly elevated ST2 gene expression in whole blood cells. This confirms the regulatory nature of the variant and provides biological plausibility for the protective allergic rhinitis association, though the periodontal findings (elevated severe periodontitis risk in A carriers) highlight that increased ST2 expression can promote inflammation in tissues where IL-33 signalling is pathological rather than protective.

The broader context for this variant is the IL1RL1 locus's robust replication in atopic disease GWAS. Ferreira et al. (Nature Genetics, 2017)⁶⁶ Ferreira et al. (Nature Genetics, 2017) established the IL1RL1 locus among the top shared signals across asthma, hay fever, and eczema in 360,838 individuals, confirming that genetic regulation of the IL-33 receptor gene has consistent effects on the spectrum of atopic conditions.

Practical Implications

For individuals carrying the protective A allele, the reduced allergic rhinitis risk from this variant operates in the same IL-33/ST2 pathway as the more extensively studied rs1420101. In clinical terms, the A allele's protective effect is modest (OR ~0.76–0.79) and the evidence is currently single-population. Individuals who are TT homozygotes at rs3771175 — the most common genotype (~78% of the population) — do not carry the expression-boosting A allele and lack this specific protective modulation of IL1RL1 expression.

The ST2 eQTL connection points toward potential personalized monitoring: measuring serum sST2 levels (available as a clinical biomarker, routinely ordered in heart failure monitoring) provides a direct readout of the IL-33 decoy receptor output that this variant modulates. Lower sST2 in TT homozygotes with atopic symptoms supports more aggressive trigger avoidance and earlier consideration of type-2 pathway-targeting biologics.

Interactions

rs3771175 occupies the same IL-33/ST2 signaling axis as the primary IL1RL1 GWAS variants rs1420101 and rs11685480 (which regulate sST2 levels through promoter-specific eQTL effects) and the upstream IL33 variants rs1342326 and rs992969 (which regulate IL-33 ligand expression). As a 3'UTR variant with a distinct regulatory mechanism (transcript stability) from the intronic eQTLs at rs1420101, rs3771175 may additively modulate IL1RL1 expression alongside the promoter-acting variants. The receptor-side genetic architecture at this locus likely produces a range of sST2 outputs depending on which combination of these variants an individual carries. Direct compound studies combining rs3771175 with rs1420101 in atopic disease cohorts have not been published to date.